An updated systematic review and statistical comparison of standardised mean outcomes for the use of botulinum toxin in the management of lower urinary tract disorders

European Urology

Volumn 65, Issue 5, 2014, Pages 981-990

  Mangera, Altaf ^a   Apostolidis, Apostolos ^b   Andersson, Karl Eric ^c   Dasgupta, Prokar ^d   Giannantoni, Antonella ^e   Roehrborn, Claus ^f   Novara, Giacomo ^g   Chapple, Christopher ^a  

^a ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

^d KING'S COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY OF PERUGIA   (Italy)

^f UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^g UNIVERSITY OF PADOVA   (Italy)

Author keywords

AbobotulinumtoxinA; Benign prostatic obstruction; Bladder outflow obstruction; Bladder pain syndrome; Botox; Botulinum toxin; Detrusor sphincter dyssynergia; Dysport; Idiopathic detrusor overactivity; Interstitial cystitis; Neurogenic detrusor overactivity; OnabotulinumtoxinA; Overactive bladder; Systematic review

Indexed keywords

BOTULINUM TOXIN A;

BENIGN PROSTATIC ENLARGEMENT; HUMAN; INTERNATIONAL PROSTATE SYMPTOM SCORE; LOWER URINARY TRACT SYMPTOM; MAXIMUM CYSTOMETRIC CAPACITY; MAXIMUM DETRUSOR PRESSURE; NEUROGENIC DETRUSOR OVERACTIVITY; NONNEUROGENIC LOWER URINARY TRACT DISEASE; OVERACTIVE BLADDER; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROSTATE VOLUME; REFLEX VOLUME; RENAL SYSTEM PARAMETERS; REVIEW; STATISTICAL ANALYSIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME; URINARY TRACT INFECTION; URODYNAMICS;

ABOBOTULINUMTOXINA; BENIGN PROSTATIC OBSTRUCTION; BLADDER OUTFLOW OBSTRUCTION; BLADDER PAIN SYNDROME; BOTOX; BOTULINUM TOXIN; DETRUSOR SPHINCTER DYSSYNERGIA; DYSPORT; IDIOPATHIC DETRUSOR OVERACTIVITY; INTERSTITIAL CYSTITIS; NEUROGENIC DETRUSOR OVERACTIVITY; ONABOTULINUMTOXINA; OVERACTIVE BLADDER; SYSTEMATIC REVIEW;

ATAXIA; BOTULINUM TOXINS, TYPE A; HUMANS; MALE; NEUROMUSCULAR AGENTS; PROSTATISM; URINARY BLADDER DISEASES; URINARY BLADDER, NEUROGENIC; URINARY BLADDER, OVERACTIVE; URINARY TRACT INFECTIONS; URODYNAMICS;

EID: 84896399966     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2013.10.033     Document Type: Review

References (34)

1. A. Mangera, K.E. Andersson, and A. Apostolidis et al. Contemporary management of lower urinary tract disease with botulinum toxin A: a systematic review of Botox (onabotulinumtoxinA) and Dysport (abobotulinumtoxinA) Eur Urol 60 2011 784 795
2. P.M. Rothwell External validity of randomised controlled trials: "to whom do the results of this trial apply?" Lancet 365 2005 82 93
3. A. Liberati, D.G. Altman, and J. Tetzlaff et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration BMJ 339 2009 b2700
4. A. Apostolidis, P. Dasgupta, and P. Denys et al. Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European consensus report Eur Urol 55 2009 100 120
5. Higgins JPT, Altman DG. Assessing risk of bias in included studies. In Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions. The Cochrane Collaboration Web site. http://www.cochrane.org/ training/cochrane-handbook. Updated March 2011.
6. A. Apostolidis, C. Thompson, X. Yan, and S. Mourad An exploratory, placebo-controlled, dose-response study of the efficacy and safety of onabotulinumtoxinA in spinal cord injury patients with urinary incontinence due to neurogenic detrusor overactivity World J Urol 31 2013 1469 1474
7. Y.C. Chen, and H.C. Kuo The therapeutic effects of repeated detrusor injections between 200 or 300 units of onabotulinumtoxinA in chronic spinal cord injured patients Neurourol Urodyn 33 2014 129 134
8. F. Cruz, S. Herschorn, and P. Aliotta et al. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial Eur Urol 60 2011 742 750
9. D. Ginsberg, A. Gousse, and V. Keppenne et al. Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity J Urol 187 2012 2131 2139
10. S. Herschorn, J. Gajewski, and K. Ethans et al. Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial J Urol 185 2011 2229 2235
11. W. Altaweel, A. Mokhtar, and D.M. Rabah Prospective randomized trial of 100u vs 200u Botox in the treatment of idiopathic overactive bladder Urol Ann 3 2011 66 70
12. C. Chapple, K.D. Sievert, and S. MacDiarmid et al. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial Eur Urol 64 2013 249 256
13. P. Denys, L. Le Normand, and I. Ghout et al. Efficacy and safety of low doses of onabotulinumtoxinA for the treatment of refractory idiopathic overactive bladder: a multicentre, double-blind, randomised, placebo-controlled dose-ranging study Eur Urol 61 2012 520 529
14. V.W. Nitti, R. Dmochowski, and S. Herschorn et al. OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial J Urol 189 2013 2186 2193
15. D.G. Tincello, R.K. Owen, M.C. Slack, and K.R. Abrams Validation of the Patient Global Impression scales for use in detrusor overactivity: secondary analysis of the RELAX study BJOG 120 2013 212 216
16. M. Marberger, E. Chartier-Kastler, and B. Egerdie et al. A randomized double-blind placebo-controlled phase 2 dose-ranging study of onabotulinumtoxinA in men with benign prostatic hyperplasia Eur Urol 63 2013 496 503
17. J. Grosse, G. Kramer, and G. Jakse Comparing two types of botulinum-A toxin detrusor injections in patients with severe neurogenic detrusor overactivity: a case-control study BJU Int 104 2009 651 656
18. R. Dmochowski, C. Chapple, and V.W. Nitti et al. Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial J Urol 184 2010 2416 2422
19. A.G. Visco, L. Brubaker, and H.E. Richter et al. Anticholinergic therapy vs. onabotulinumtoxina for urgency urinary incontinence N Engl J Med 367 2012 1803 1813
20. H.C. Kuo Bladder base/trigone injection is safe and as effective as bladder body injection of onabotulinumtoxinA for idiopathic detrusor overactivity refractory to antimuscarinics Neurourol Urodyn 30 2011 1242 1248
21. R.P. Manecksha, I.M. Cullen, and S. Ahmad et al. Prospective randomised controlled trial comparing trigone-sparing versus trigone-including intradetrusor injection of abobotulinumtoxinA for refractory idiopathic detrusor overactivity Eur Urol 61 2012 928 935
22. H.C. Kuo Comparison of effectiveness of detrusor, suburothelial and bladder base injections of botulinum toxin a for idiopathic detrusor overactivity J Urol 178 2007 1359 1363
23. P. Gallien, J.M. Reymann, G. Amarenco, B. Nicolas, M. de Sèze, and E. Bellissant Placebo controlled, randomised, double blind study of the effects of botulinum A toxin on detrusor sphincter dyssynergia in multiple sclerosis patients J Neurol Neurosurg Psychiatry 76 2005 1670 1676
24. G. Maria, G. Brisinda, I.M. Civello, A.R. Bentivoglio, G. Sganga, and A. Albanese Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study Urology 62 2003 259 264
25. Y.C. Chuang, P.H. Chiang, N. Yoshimura, F. De Miguel, and M.B. Chancellor Sustained beneficial effects of intraprostatic botulinum toxin type A on lower urinary tract symptoms and quality of life in men with benign prostatic hyperplasia BJU Int 98 2006 1033 1037
26. E.D. Crawford, K. Hirst, and J.W. Kusek et al. Effects of 100 and 300 units of onabotulinum toxin A on lower urinary tract symptoms of benign prostatic hyperplasia: a phase II randomized clinical trial J Urol 186 2011 965 970
27. J. Silva, C. Silva, and L. Saraiva et al. Intraprostatic botulinum toxin type a injection in patients unfit for surgery presenting with refractory urinary retention and benign prostatic enlargement. Effect on prostate volume and micturition resumption Eur Urol 53 2008 153 159
28. H.P. Gottsch, J.L. Miller, C.C. Yang, and R.E. Berger A pilot study of botulinum toxin for interstitial cystitis/painful bladder syndrome Neurourol Urodyn 30 2011 93 96
29. H.C. Kuo, and M.B. Chancellor Comparison of intravesical botulinum toxin type A injections plus hydrodistention with hydrodistention alone for the treatment of refractory interstitial cystitis/painful bladder syndrome BJU Int 104 2009 657 661
30. H.C. Kuo Repeated onabotulinumtoxin-a injections provide better results than single injection in treatment of painful bladder syndrome Pain Physician 16 2013 E15 E23
31. D. Pistolesi, G. Giannarini, G. Stampacchia, and C. Selli Should we stop using botulinum neurotoxin type a in patients with neurogenic detrusor overactivity after development of secondary resistance? Eur Urol 60 2011 872 873
32. K.F. Neel, S. Soliman, M. Salem, M. Seida, H. Al-Hazmi, and A. Khatab Botulinum-A toxin: solo treatment for neuropathic noncompliant bladder J Urol 178 2007 2593 2597
33. M.P. Pascali, G. Mosiello, A. Marciano, M.L. Capitanucci, A.M. Zaccara, and M. De Gennaro A simplified technique for botulinum toxin injections in children with neurogenic bladder J Urol 185 2011 2558 2562
34. S. Safari, S. Jamali, P. Habibollahi, H. Arshadi, F. Nejat, and A.M. Kajbafzadeh Intravesical injections of botulinum toxin type A for management of neuropathic bladder: a comparison of two methods Urology 76 2010 225 230